Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 15

1.

Using Insulin Infusion Sets in CSII for Longer Than the Recommended Usage Time Leads to a High Risk for Adverse Events: Results From a Prospective Randomized Crossover Study.

Pfützner A, Sachsenheimer D, Grenningloh M, Heschel M, Walther-Johannesen L, Gharabli R, Klonoff D.

J Diabetes Sci Technol. 2015 Sep 3;9(6):1292-8. doi: 10.1177/1932296815604438.

PMID:
26341262
2.

Insulin analogs--is there a compelling case to use them? No!

Davidson MB.

Diabetes Care. 2014 Jun;37(6):1771-4. doi: 10.2337/dc13-2915.

3.

Stability and performance of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion: a systematic review.

Kerr D, Wizemann E, Senstius J, Zacho M, Ampudia-Blasco FJ.

J Diabetes Sci Technol. 2013 Nov 1;7(6):1595-606. Review.

4.

Race, socioeconomic status, and treatment center are associated with insulin pump therapy in youth in the first year following diagnosis of type 1 diabetes.

Lin MH, Connor CG, Ruedy KJ, Beck RW, Kollman C, Buckingham B, Redondo MJ, Schatz D, Haro H, Lee JM, Tamborlane WV, Wood JR; Pediatric Diabetes Consortium.

Diabetes Technol Ther. 2013 Nov;15(11):929-34. doi: 10.1089/dia.2013.0132. Epub 2013 Jul 19.

5.

Conformational dynamics of insulin.

Hua QX, Jia W, Weiss MA.

Front Endocrinol (Lausanne). 2011 Oct 18;2:48. doi: 10.3389/fendo.2011.00048. eCollection 2011.

6.

Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations.

Uy J, Fogelfeld L, Guerra Y.

Diabetes Metab Syndr Obes. 2012;5:1-10. doi: 10.2147/DMSO.S15404. Epub 2012 Jan 10.

7.

Insulin glulisine in the management of diabetes.

Yamada S.

Diabetes Metab Syndr Obes. 2009 Jul 7;2:111-5.

8.

Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy-trouble starts on day 3.

Schmid V, Hohberg C, Borchert M, Forst T, Pfützner A.

J Diabetes Sci Technol. 2010 Jul 1;4(4):976-82.

9.

Patient treatment satisfaction after switching to NovoMix® 30 (BIAsp 30) in the IMPROVE™ study: an analysis of the influence of prior and current treatment factors.

Brod M, Valensi P, Shaban JA, Bushnell DM, Christensen TL.

Qual Life Res. 2010 Nov;19(9):1285-93. doi: 10.1007/s11136-010-9699-0. Epub 2010 Jul 4.

10.

An Achilles' heel in an amyloidogenic protein and its repair: insulin fibrillation and therapeutic design.

Yang Y, Petkova A, Huang K, Xu B, Hua QX, Ye IJ, Chu YC, Hu SQ, Phillips NB, Whittaker J, Ismail-Beigi F, Mackin RB, Katsoyannis PG, Tycko R, Weiss MA.

J Biol Chem. 2010 Apr 2;285(14):10806-21. doi: 10.1074/jbc.M109.067850. Epub 2010 Jan 27.

11.

An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK.

Pratoomsoot C, Smith HT, Kalsekar A, Boye KS, Arellano J, Valentine WJ.

Diabet Med. 2009 Aug;26(8):803-14. doi: 10.1111/j.1464-5491.2009.02775.x. Review.

12.

Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes: a randomized controlled trial.

Logtenberg SJ, Kleefstra N, Houweling ST, Groenier KH, Gans RO, van Ballegooie E, Bilo HJ.

Diabetes Care. 2009 Aug;32(8):1372-7. doi: 10.2337/dc08-2340. Epub 2009 May 8.

13.

Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis.

Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H.

CMAJ. 2009 Feb 17;180(4):385-97. doi: 10.1503/cmaj.081041.

14.

Past, present, and future of insulin pump therapy: better shot at diabetes control.

Sherr J, Tamborlane WV.

Mt Sinai J Med. 2008 Aug;75(4):352-61. doi: 10.1002/msj.20055. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk